GH treatment (Genotropin)
ApprovedSmall molecule
GH treatment (Genotropin) is one of 47 small molecule programs targeting Prader-Willi syndrome. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Prader-Willi Syndrome
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Topamax
WWim Janssens
Approved
Intuniv
PPromius Pharma, LLC
Approved
Growth Hormone
PfizerApproved
Wakix
HHarmony Biosciences Management, Inc.
Phase 3
Pabal
AACADIA Pharmaceuticals Inc.
Phase 3
Genotropin
PfizerPhase 3
Rimonabant
SanofiPhase 3
Sandostatin LAR
NovartisPhase 3
Nutropin AQ
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GH treatment (Genotropin). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- RRabin Medical Center